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30* Quality improvement in newborn screening for cystic ﬁbrosis by
process failure mode effects analysis (PFMEA)
P.M. Farrell1, M.K. Kloosterboer1, R.C. Reynolds1, Z. Li1. 1UW School of
Medicine and Public Health, Madison, WI, USA
Cystic ﬁbrosis (CF) newborn screening (NBS) in the US has expanded rapidly to
include all states except one, but issues have arisen regarding quality assurance.
To address the entire CF NBS process we have completed a quality improvement
(QI) project integrating methods used in other industries such as aviation but never
previously applied to NBS, namely PFMEA exercises. Speciﬁcally, we drafted a
ﬂowchart of the entire CF NBS process, as well as a best IRT/DNA practices
protocol, then generated a list of potential errors in this multi-step system, and rated
them on a 1 to 10 scale each for severity, occurrence probability, and detectability;
the product of these is the Risk Priority Number or RPN. Rating a list of 112
potential errors in Denver CO, Boston MA, and Madison WI by groups of NBS
experts (N = 22) revealed that the most severe potential problems (RPN values)
are: (1) parents misunderstand genetic counseling information (203); (2) missed
babies due to NICU transfer (180); (3) IRT cutoff errors leading to false negative
outcome (165); (4) babies with confusing or similar names (160); (5) primary care
physicians not understanding NBS results and being unable to accurately explain
them to parents (159); (6) birth hospitals entering the wrong data, i.e., clerical errors
(158); (7) primary care physicians understanding the NBS results but not how to
communicate properly without a scripted message (157); (8) babies never screened
(153); (9) nurses or lab technicians obtaining and processing the wrong NBS card
(153); (10) false negative NBS test results (148). It was revealing, surprising, and
signiﬁcant that 60% of the most serious potential errors relate to communication
challenges. These results will help with QI efforts.
Supported by: National Institutes of Health.
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Background: Although newborn screening for CF (NBSCF) is included in many
routine newborn screening programs, there is no ideal test.
Aim: to assess the test characteristics of 2 new strategies for NBSCF.
Methods: In 2008 NBSCF was added to routine NBS in 4 Dutch provinces.
In each sample screening was performed by 2 strategies. The 1st strategy used
immunoreactive trypsin (IRT) and pancreatitis-associated protein (PAP). The test
was considered positive with concentrations of IRT= 50 and PAP= 1.8 or IRT= 100
and PAP= 1.0 (all mg/l). For the 2nd method samples with IRT= 50 were analyzed
for 36 CF-mutations. An extended gene-analysis (EGA) was performed in samples
with 1 CF-mutation. Tests were positive when 2 CF-mutations were identiﬁed.
Results: Of the 72874 screened neonates 127 had a positive test with the IRT-
PAP, among those 10 CF patients were identiﬁed. With the IRT-DNA-EGA 18
positive tests identiﬁed 11 CF-patients. IRT-DNA-EGA also revealed 84 carriers
and 7 compound heterozygotes with R117H-7T as 2nd mutation. To assess the
sensitivity a retrospective analysis with the 2 strategies was performed in heel prick
samples of 18 known CF-patients. The IRT-PAP identiﬁed 13, the IRT-DNA-EGA
18 patients. Speciﬁcity and PPV for the IRT-PAP were 99.8 and 8.2%, while for
the IRT-DNA-EGA these were 99.99 and 61%. Sensitivity calculated on the results
of the screening program and the retrospective analysis was 82 respectively 100%.
Conclusion: Compared to current NBSCF-strategies, an improved test performance
of the IRT-DNA-EGA strategy was found, but not of the IRT-PAP strategy.
32* Cystic Fibrosis (CF) Newborn Screening (NBS) – Comparison
of an IRT-PAP with an IRT-DNA based protocol in a German
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G.F. Hoffmann1. 1University Children’s Hospital, Heidelberg, Germany
The effect of NBS for CF has been extensively studied. Today there is evidence
that CF patients diagnosed by NBS show less nutritional deﬁciencies and a reduced
morbidity compared to clinically diagnosed CF patients. In Germany there is so far
no nationwide routine CF NBS program.
All current CF NBS protocols start with quantiﬁcation of immunoreactive trypsino-
gen (IRT) as 1st tier in dry blood. In case of elevated IRT most NBS protocols
analyse a region dependent panel of CF causing mutations as 2nd tier (IRT-DNA).
If 1 or 2 mutations are detected, sweat testing is performed as conﬁrmation. The
disadvantage of IRT-DNA is the detection of healthy carriers. Recent data (Sarles
et al. Pediatrics 2005) show that consecutive analysis of IRT and pancreatitis
associated protein (PAP) may represent an alternative method (IRT-PAP).
The aim of our study is to compare both protocols in a German population
(NBS Centre Heidelberg). The tests are carried out in heel prick dry blood spots
from routine screening after written parental consent. Is IRT elevated (>99.0 P.) a
parallel detection of PAP and a screening for 4 CF causing mutations (delF508,
G551D, R553X, G542X) follows. A positive result in either of the protocols results
in a sweat test performed in a certiﬁed CF centre. From April until November
2008 28663 children were screened for CF. 324 (1.1%) showed an elevated IRT,
61 (0.21%) of them were tested positive in a 2nd tier. In 7 children (0.024%) CF
was conﬁrmed.
We expect important information about the feasibility and reliability of a biochem-
ically based CF NBS in comparison to a DNA based screening. Furthermore, the
project represents a milestone on the way to a nationwide CF NBS in Germany.
Supported by: Dietmar-Hopp-Stiftung.
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Biomarkers obtained by rapid and non-invasive methods could be used in the
precocious detection of exacerbations or as prognostic indicators in CF. Our goal
was to search for lipid signatures characteristic of CF patients in blood plasma.
Samples from 121 individuals (53 CF patients, 18 healthy children and 49 healthy
parents – heterozygotes) were collected at the Institute for Mother and Child (War-
saw). Organic extraction was followed by elution through SepPak-C18 cartridges
by methyl formate. Extracts were analyzed by mass spectrometry (MALDI-TOF).
Data were acquired in the positive and negative reﬂector mode between 200 and
1500 m/z. Ion signatures were compared by the ClinProTools software (Bruker
Daltonics). Twenty one peaks, found statistically signiﬁcant, were analyzed by LC-
ESI-MS/MS for identiﬁcation. Twelve of them were consistently upregulated (3)
or downregulated (9) in CF patients as compared to heterozygotes and healthy
subjects. Downregulated signatures were identiﬁed as seven phosphatidylcholine
and two lysophosphatidylcholine species, some of them containing polyunsaturated
acyl chains. Upregulated ions included a triglyceride adduct (m/z 881.8), and two
ion signatures (m/z 335.1 and 337.1) coincident with the masses of a number
of arachidonic acid derivatives. These results are consistent with the altered
arachidonic acid metabolism and fatty acid proﬁles characteristic of CF patients, and
show MALDI-TOF and ClinProTools, together with LC-ESI-MS/MS, as a suitable
methodology for the search of lipid markers in CF.
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